In this audio webinar, Danny Cohen and I explain why we are bullish on Calithera Biosciences (CALA). We go over the technology, current data set, upcoming catalysts, and why we believe a deal with $BMY is near to come. We also…
Tag: renal cell
AVEO Pharma’s Tivozanib Likely To Be Approved
With the current record market run, small cap biopharmas have kept pace and continue to trend higher, being one of the best sectors for both trading and investing over the past year. With 39 new drugs approved, 2012 showed the…
